VA study to examine psilocybin for depression and PTSD

The Department of Veterans Affairs has launched a major clinical trial to study whether psilocybin, the active compound in psychedelic mushrooms, can effectively treat veterans suffering from treatment-resistant depression and post-traumatic stress disorder. The study, called the Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression or PIVOT, will enroll at least 240 veterans across five VA medical centers and run through June 2031. VA Secretary Doug Collins emphasized that the trial represents the department's commitment to exploring new treatment options for veterans whose mental health conditions have not responded to currently available therapies.

This research initiative follows a smaller study published in July by Ohio State University that showed promising results for veterans with severe PTSD. In that 12-person trial, participants received eight hours of psychotherapy combined with two doses of synthetic psilocybin and integrative therapy. Seventy-five percent of participants no longer met clinical criteria for PTSD after treatment, with no serious adverse effects reported. The most common side effects were headache, anxiety, and dizziness, and notably, no participants experienced suicidal ideation or behavior during the study.

The PIVOT trial will specifically target veterans diagnosed with major depressive disorder who have not responded to existing treatments, including some participants who also have PTSD diagnoses. This focus on treatment-resistant cases is significant because many veterans cycle through multiple medications and therapies without finding relief, leaving them with limited options and ongoing suffering that affects their daily functioning and quality of life.

The study will be conducted as a double-blind, randomized trial at five VA facilities: Birmingham VA Health Care System and Tuscaloosa VA Medical Center in Alabama, VA Portland Health Care System in Oregon, Corporal Michael Crescenz VA Medical Center in Philadelphia, and VA Puget Sound Health Care System in Seattle. Participants will receive either psilocybin or a placebo along with therapeutic support, followed by a second dose one month later. Veterans will be evaluated two to four weeks after each session and receive follow-up care six months after their participation ends. VA officials stressed that the study will use pharmaceutical-grade drugs administered in safe, controlled clinical settings.

This trial is part of a broader federal push to explore psychedelic therapies for mental health treatment. President Trump signed an executive order in April directing the FDA to accelerate review of psychedelic therapies, and the VA is currently involved in 20 clinical trials examining treatments including MDMA and LSD. However, the path forward remains uncertain, as the FDA rejected an application to approve MDMA for PTSD treatment in 2024, requesting additional safety and efficacy research.

For disabled veterans struggling with depression and PTSD, this study represents a potential new avenue for relief, though it remains in the research phase. The VA strongly cautioned veterans against self-medicating with psychedelics or replacing prescribed treatments with unprescribed substances, emphasizing that proven, evidence-based treatments are currently available at VA facilities. The department's investment in this research acknowledges both the severity of treatment-resistant mental health conditions among veterans and the need for additional therapeutic options.

Veterans interested in participating in clinical trials for mental health treatments should contact their VA mental health provider to discuss eligibility and available studies at their local facility. Those currently struggling with depression or PTSD should continue working with their VA care team on existing evidence-based treatments while researchers work to determine whether psychedelic-assisted therapy can become a safe, approved option in the future.